Anzeige
Mehr »
Mittwoch, 13.05.2026 - Börsentäglich über 12.000 News
Bahnbrechende KI-Lösung "Ohne Nadelstiche" als Ersatz für herkömmliche Bluttests "unlocked"?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QHK9 | ISIN: US82835W1080 | Ticker-Symbol:
NASDAQ
13.05.26 | 21:59
8,010 US-Dollar
-7,18 % -0,620
1-Jahres-Chart
ARS PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ARS PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur ARS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:34ARS Pharmaceuticals ernennt Donn Casale zum neuen President1
14:18ARS Pharmaceuticals appoints Donn Casale as president1
ARS PHARMACEUTICALS Aktie jetzt für 0€ handeln
14:15ARS Pharmaceuticals, Inc. - 8-K, Current Report1
17.04.Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver2
15.04.ARS Pharmaceuticals, Inc.: neffy (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)2
09.04.Northland initiates ARS Pharmaceuticals stock with outperform rating1
09.04.Northland stuft ARS Pharmaceuticals mit "Outperform" ein und setzt Kursziel auf 25 US-Dollar1
03.04.Weekly Buzz: ARS Pharmaceuticals Gains FDA Nod; Novo Nordisk received FDA approval for Awiqli; EU Expands Kerendia Label; Eli Lilly Acquires Centessa Pharmaceuticals; Biogen Snaps Up Apellis Pharmaceuticals5.881BASEL (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S., EU, and China, acquisitions, a few key trial goal misses and positive clinical trial data readouts...
► Artikel lesen
27.03.William Blair reiterates Outperform on ARS Pharma stock after FDA label update4
27.03.ARS Pharma gains FDA clearance to remove age restriction from neffy1
27.03.ARS Pharma: FDA Approves Label Update For Theneffy 1 Mg To Remove Age Criteria-
27.03.ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy 1 mg (epinephrine nasal spray) Label353Children were previously required to weigh =33 lbs. and neffy 1 mg dose - approval enables families of younger children within the weight range to access a needle-free epinephrine without age restrictions...
► Artikel lesen
10.03.Leerink raises ARS Pharmaceuticals stock price target on sales expansion4
09.03.ARS Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
09.03.ARS Pharmaceuticals outlines sales force expansion and digital strategy for neffy growth while maintaining SG&A in 20261
09.03.ARS Pharmaceuticals: Q4 Earnings Insights1
09.03.ARS Pharmaceuticals GAAP EPS of -$1.74 beats by $0.02, revenue of $84.28M beats by $2.6M2
09.03.ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy (epinephrine nasal spray) Commercialization1.271neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million...
► Artikel lesen
09.03.ARS Pharmaceuticals, Inc. - 10-K, Annual Report1
09.03.ARS Pharmaceuticals, Inc. - 8-K, Current Report2
Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1